Posts by: Jose Marques Lopes, PhD

cystic fibrosis, News

An exploratory Phase 1 trial showed that repeated intranasal treatment with the therapy eluforsen improved CFTR protein activity in adults with cystic fibrosis (CF) carrying F508del mutations in both ... Read more

January 11, 2019January 11, 2019

WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials

cystic fibrosis, News

The World Health Organization (WHO) approved ensifentrine as the recommended name to identify the cystic fibrosis (CF) treatment candidate RPL554. Verona Pharma’s ensifentrine is an inhaled inhibitor of the enzymes phosphodiesterase ... Read more

December 17, 2018December 17, 2018

Health Canada Approves Orkambi to Treat Preschoolers with Two F508del Mutations

cystic fibrosis, News

Health Canada has approved Orkambi (ivacaftor/lumacaftor) to treat preschoolers with cystic fibrosis (CF) who carry the F508del mutation in both gene copies of the CFTR gene. Orkambi, developed by Vertex Pharmaceuticals, ... Read more

December 6, 2018December 6, 2018

Inhaled Hypertonic Saline Improves Lung Health in Preschoolers with CF, Study Shows

cystic fibrosis, News

Preschoolers with cystic fibrosis (CF) treated with inhaled hypertonic saline in a clinical trial showed significant improvement in lung function, PARI, the company whose solution and equipment was used in the ... Read more

November 29, 2018November 29, 2018

Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show

cystic fibrosis, News

Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved lung function and was well-tolerated by cystic fibrosis (CF) patients, ages 12 ... Read more

November 26, 2018November 26, 2018

P. aeruginosa Toxin May Be Reason for Single Strains Found in CF Infections, Study Reports

cystic fibrosis, News

A protein toxin called Tse7 is used by Pseudomonas aeruginosa to kill neighboring bacteria, and may help explain why lung infections in cystic fibrosis patients are often dominated by a ... Read more

November 14, 2018November 14, 2018

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Suggests

cystic fibrosis, News

Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitro efficacy against multidrug-resistant Pseudomonas aeruginosa collected from the sputum of cystic fibrosis (CF) patients, according to a recent study. The study, “Multidrug-resistant Pseudomonas aeruginosa from ... Read more

September 20, 2018September 20, 2018

FDA Gives Green Light to 2 Trials for AB-PA01, Potential Therapy Against P. aeruginosa Infections

cystic fibrosis, News

The U.S. Food and Drug Administration gave positive feedback to the design of AmpliPhi Biosciences’ two proposed clinical trials of its Pseudomonas aeruginosa-targeting treatment candidate AB-PA01, the company announced ... Read more

August 29, 2018August 29, 2018

Measuring D-Lactate in Blood May Indicate Pancreatic Insufficiency in CF Patients, Study Suggests

cystic fibrosis, News

Blood levels of D-lactate may be markers of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF), according to preliminary data from a new study. The research, “Serum ... Read more

August 21, 2018August 21, 2018

Orkambi Soon to Be Added to Public Health Plan for CF Patients in Australia

cystic fibrosis, News

Orkambi (lumacaftor/ivacaftor), a treatment for cystic fibrosis (CF) patients in Australia age 6 and up, is closer to being subsidized by the government, according to Vertex Pharmaceuticals, the medication’s ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Eluforsen Improves CFTR Protein Function in CF Patients with F508del Mutations, Phase 1 Trial Shows

WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials

Health Canada Approves Orkambi to Treat Preschoolers with Two F508del Mutations

Inhaled Hypertonic Saline Improves Lung Health in Preschoolers with CF, Study Shows

Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show

P. aeruginosa Toxin May Be Reason for Single Strains Found in CF Infections, Study Reports

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Suggests

FDA Gives Green Light to 2 Trials for AB-PA01, Potential Therapy Against P. aeruginosa Infections

Measuring D-Lactate in Blood May Indicate Pancreatic Insufficiency in CF Patients, Study Suggests

Orkambi Soon to Be Added to Public Health Plan for CF Patients in Australia

Pin It on Pinterest